Search Results

â?¢Patients must have confirmed multiple myeloma meeting criteria with symptomatic disease requiring treatment. Patients considered to have high risk disease in first remission or Patients with relapsed myeloma responding to salvage therapy based on the International Uniform Response Criteria. â?¢Patients must be planning to proceed to single autologous transplantation according to institutional standards and must receive this transplantation prior to implementation of GDC-0449. â?¢Concomitant bisphosphonate use is allowed as clinically indicated. â?¢Age greater than 18 years â?¢Life expectancy of greater than 6 months. â?¢ECOG performance status less than 2 (Karnofsky greater than 60%; Patients must have adequate liver, kidney and marrow function. â?¢Women of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry,for the duration of study participation, and for at least 12 months post-treatment. â?¢Pregnancy Testing. Women of childbearing potential are required to have a negative serum pregnancy test within 24 hours prior to the first dose of GDC-0449 (serum or urine). HIV-positive patients without a prior AIDS-defining illness and a CD4 count greater than 400/millimeter3 and either do not require anti-HIV therapy or are taking anti-HIV therapy that would not interfere with GDC-0449 (e.g. not taking zidovudine, protease inhibitors or non-nucleoside reverse transcriptase inhibitors) are eligible. â?¢Ability to understand and the willingness to sign a written informed consent document. â?¢They are therapeutic on a stable warfarin dose, monitored weekly, with INR target range no greater than 3. Other anticoagulants, including low molecular weight heparin such as Lovenox) and Arixtra)are permitted. â?¢They have no active bleeding or pathological condition that carries high risk of bleeding.